The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy . Full details of the evidence and the committee's discussion are in evidence review E: ...

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR, 22 patients (11.1%) with severe NPDR ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and severe non-proliferative diabetic retinopathy to proliferative diabetic ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

EyePoint Pharmaceuticals, Inc.’s EYPT share price has dipped by 15.13%, which has investors questioning if this is right time to buy.